In another meta-analysis using pathology as a gold standard [26], PET/CT with 68Ga-PSMA-targeted agents at initial PCa staging demonstrated a sensitivity and specificity of 74% and 96%, respectively. This evidence concerns the gene FOLH1 and posterior cortical atrophy.